Zyvox

Type: Product
Name: Zyvox
First reported 11 hours ago - Updated 11 hours ago - 1 reports

A Linezolid Prior Authorization Program: Clinical and Economic Outcomes

Catherine I. Starner, PharmD, BCPS; R. Scott McClelland, PharmD; Yang Qiu, MS; Richard A. Zabinski, PharmD; Nancy Cotter, PharmD; and Patrick P. Gleason, PharmD, BCPS, FCCPAs pharmacy benefit costs continue to rise, health insurers and plan sponsors are ... [Published American Journal of Managed Care - 11 hours ago]
Entities: Zyvox, Antibiotic, pharmacy
First reported Apr 09 2014 - Updated Apr 10 2014 - 8 reports

The Zacks Analyst Blog Highlights:MannKind, Cubist, Medicines Co., Amgen and Halozyme

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact ... [Published KHNL News 8 - Apr 10 2014]
First reported Apr 08 2014 - Updated Apr 08 2014 - 1 reports

In the Highly Competitive MRSA cSSSI Market, Cubist''s Sivextro Will be Positively Differentiated from Current and Emerging Therapies

/PRNewswire/ -- Decision Resources Group finds that following its launch, Cubist''s second generation oxazolidinone Sivextro will be highly differentiated from other anti-MRSA (methicillin-resistant Staphylococcus aureus ) agents for the treatment of ... [Published Asian Hospital & Healthcare Management - Apr 08 2014]
First reported Apr 08 2014 - Updated Apr 08 2014 - 1 reports

Pfizer Blockbuster Zyvox Under Attack

Incoming competition for Pfizer 's ( NYSE: PFE     ) $1.4 billion Zyvox market is threatening on multiple fronts. With several important revenue streams drying up, this one has become more important than ever to the drug company.Recently, an FDA advisory ... [Published Motley Fool Discussion Boards - Apr 08 2014]
First reported Apr 04 2014 - Updated Apr 04 2014 - 1 reports

What's Next for Cubist Pharmaceuticals Inc. and Durata Therapeutics, Inc.?

Cubist Pharmaceuticals ( NASDAQ: CBST     ) and Durata Therapeutics ( NASDAQ: DRTX     ) both won this week with nods by the FDA's advisory panels on each company's antibacterial agents.In two unanimous votes, the FDA panels agreed on the safety and ... [Published Motley Fool Discussion Boards - Apr 04 2014]
First reported Apr 02 2014 - Updated Apr 02 2014 - 1 reports

Unanimous FDA advisory panel backing for Cubist’s Sivextro

The US Food and Drug Administration’s Anti-Infective Drugs Advisory Committee (AIDAC) on Monday voted unanimously (14-0) to recommend approval of Cubist Pharmaceutical’s (Nasdaq: CBST) investigational antibiotic Sivextro (tedizolid phosphate), for the ... [Published Pharma Letter - Apr 02 2014]
First reported Apr 02 2014 - Updated Apr 02 2014 - 1 reports

Big Pharma Abandons New Tuberculosis Drug Research

Tuberculosis Microbe. Photo: Sanofi Pasteur. Used under Creative Commons license.Three major pharmaceutical companies - AstraZeneca, Johnson & Johnson and Pfizer - have recently delayed or canceled clinical trials for testing tuberculosis (TB) drugs in ... [Published CorpWatch - Apr 02 2014]
First reported Mar 31 2014 - Updated Apr 01 2014 - 2 reports

FDA panel endorses Cubist antibiotic

An influential advisory panel recommended Monday that the Food and Drug Administration approve a Cubist Pharmaceuticals Inc. drug to treat serious bacterial skin infections, sending the Lexington drug maker’s application to the FDA for a ruling later ... [Published Boston Globe - Apr 01 2014]
First reported Mar 31 2014 - Updated Apr 01 2014 - 3 reports

UPDATE 1-Durata's anti-infective drug shows efficacy, safety -FDA panel

March 31 (Reuters) - Durata Therapeutics Inc's drug to treat acute bacterial skin infections shows substantial evidence of safety and efficacy, a panel of advisers to the U.S. Food and Drug Administration concluded on Monday.The panel voted unanimously ... [Published CNBC - Mar 31 2014]
First reported Mar 25 2014 - Updated Mar 25 2014 - 1 reports

Five Star Stock Watch: Pfizer

If traders have been paying much attention to the market at all the past couple of days, then they know biotech and/or pharmaceutical stocks have been getting hit hard.Some of the highest flyers such as PCRX, ISIS and INCY have taken it pretty good, but ... [Published Benzinga.com - Mar 25 2014]
First reported Mar 21 2014 - Updated Mar 21 2014 - 1 reports

3 Upcoming FDA Meetings You Should be Watching

Just because we're out of earnings season doesn't mean there aren't big data-driven events happening in the health care sector. Between now and the end of the month there are three Food and Drug Administration panel meetings that are bound to tantalize ... [Published Motley Fool Discussion Boards - Mar 21 2014]
First reported Mar 19 2014 - Updated Mar 19 2014 - 1 reports

To Save Her Husband's Life, A Woman Fights For Access To TB Drugs

One year ago Pavel Rucsineanu was running out of options.Drug-resistant tuberculosis was ravaging his lungs. And the disease had evolved into an incurable form, doctors said.It's like an "infectious cancer," Dr. Tetru Alexandriuc said at the time. "We ... [Published WUWM - Mar 19 2014]

Quotes

...In addition, in a recent article on Forbes , they observe that " The investigators did not explore whether other PDE5A inhibitors, including tadalafil (Cialis) and vardenafil (Levitra), were associated with melanoma, since these drugs were not available at the start of the study. But in their discussion they point out that because these drugs are longer-acting they may potentially result in an even greater increase in risk for melanoma." . It is interesting that we saw a severe price response in Pfizer, with little to no impact on Bayer (OTCPK: BAYRY ) and GlaxoSmithKline GSK ) who manufacture...
...less well-tolerated parenteral antibiotics, developers can highlight safety and delivery improvements to capitalize on market opportunities. "Therapies that can help promote early discharge or reduce hospital admissions will gain favorable uptake as healthcare providers aim to reduce hospital-associated costs. Therefore, agents providing convenient use in the outpatient setting, including availability in IV and oral formulations, shorter courses of therapy, or infrequent dosing, will be highly differentiated in this crowded market segment."
...“Little company R&D (research and development) is devoted to basic research,” write Donald Light and Rebecca Warburton in a 2011 article titled " “Although industry association reports, based on unverified numbers from its members, claim that companies invest on average 17–19 percent of sales in R&D…the net corporate investment in research to discover important new drugs is about 1.2 percent of sales.”"
"I'm wondering how many people will get a shot of this, go out the door and never come back" said Dr. Michael Neely, a panelist and associate professorprofessor of pediatrics at the University of Southern California

More Content

All (56) | News (54) | Reports (0) | Blogs (1) | Audio/Video (0) | Fact Sheets (0) | Press Releases (1)
sort by: Date | Relevance
Company Update: Pfizer Inc (NYSE:PFE) – Teva se... [Published Jutia Group - 9 hours ago]
A Linezolid Prior Authorization Program: Clinic... [Published American Journal of Managed Care - 11 hours ago]
Senior Manager, Quillivant XR Marketing [Published PharmaDiversity - Apr 17 2014]
The Zacks Analyst Blog Highlights:MannKind, Cub... [Published KHNL News 8 - Apr 10 2014]
The Zacks Analyst Blog Highlights:MannKind, Cub... [Published KATV - Apr 10 2014]
The Zacks Analyst Blog Highlights:MannKind, Cub... [Published WTen.com - Apr 10 2014]
The Zacks Analyst Blog Highlights:MannKind, Cub... [Published KSWO - Apr 10 2014]
The Zacks Analyst Blog Highlights:MannKind, Cub... [Published WAND TV - Apr 10 2014]
The Zacks Analyst Blog Highlights:MannKind, Cub... [Published PR Newswire - Apr 10 2014]
The Zacks Analyst Blog Highlights: MannKind, Cu... [Published Yahoo! Finance - Apr 10 2014]
Western student found dead outside Gunnison [Published Crested Butte News - Apr 10 2014]
Biotech Stock Roundup: MannKind Soars on Panel ... [Published Nasdaq - Apr 09 2014]
Pfizer: It Never Rains, It Pours [Published Seeking Alpha - Apr 09 2014]
In the Highly Competitive MRSA cSSSI Market, Cu... [Published Asian Hospital & Healthcare Management - Apr 08 2014]
Pfizer Blockbuster Zyvox Under Attack [Published Motley Fool Discussion Boards - Apr 08 2014]
What's Next for Cubist Pharmaceuticals Inc. and... [Published Motley Fool Discussion Boards - Apr 04 2014]
PB Girl Scouts help ‘Finish Chelsea’s Run’ in B... [Published Sandiego Newsroom - Apr 03 2014]
In the Highly Competitive MRSA cSSSI Market, Cu... [Published Freshnews.com - Apr 03 2014]
Unanimous FDA advisory panel backing for Cubist... [Published Pharma Letter - Apr 02 2014]
Big Pharma Abandons New Tuberculosis Drug Research [Published CorpWatch - Apr 02 2014]
FDA Panel Recommends 2 New Anti-MRSA Agents [Published Diabetes Care - Apr 02 2014]
Seven Exercises That Aren’t Worth Your Time [Published Sandiego Newsroom - Apr 01 2014]
Cubist Rises on Favorable FDA Panel View [Published Zacks.com - Apr 01 2014]
FDA panel endorses Cubist antibiotic [Published Boston Globe - Apr 01 2014]
FDA advisory committee finds dalbavancin safe, ... [Published Orthopedics Today - Apr 01 2014]
UPDATE 3-U.S. FDA panel votes in favor of two a... [Published Reuters UK - Mar 31 2014]
Panel recommends approval of Cubist skin treatment [Published Boston Globe - Mar 31 2014]
UPDATE 1-Durata's anti-infective drug shows eff... [Published CNBC - Mar 31 2014]
Cubist's superbug drug clears FDA panel, lines ... [Published FierceBiotech - Mar 31 2014]
Eradication of a chronic wound and driveline in... [Published 7thSpace - Mar 31 2014]
1 2
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
This is so hard [Published HealthBoards - Jan 11 2014]
I had a right THR in November. It went well until I was sent to what my dr. thought was one of the best Rehabs in the center and it was a NIGHTMARE. I urge any of you going to a Rehab to go see it first, take to the staff see what their policies are.The ...
1

Press Releases

sort by: Date | Relevance
Current MRSA Antibiotics Will Face Competition ... [Published PR Newswire - Nov 19 2013]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.